SEC Filing Summary: GSK Plc (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by GSK Plc for the reporting period ending March 31, 2026. The document discloses equity securities held by the company, specifically focusing on positions in biotechnology and pharmaceutical firms. The filing does not contain GSK Plc's own financial performance data (revenue, profit, or cash flow) but rather details its investment portfolio.
Key Financial Metrics and Portfolio Holdings
The filing lists 13 equity positions with a combined reported value of approximately $397.3 million. The portfolio is heavily concentrated in biotechnology and life sciences companies. Key holdings include:
- Wave Life Sciences Ltd: 18,245,691 shares valued at $132,281,260 (Largest position).
- Crispr Therapeutics AG: 3,220,627 shares valued at $153,205,226 (Highest share count value).
- Vir Biotechnology Inc: 8,550,954 shares valued at $76,616,548.
- BioNTech SE: 889,824 shares valued at $79,087,557.
- Spero Therapeutics Inc: 9,190,606 shares valued at $21,506,018.
All listed positions are reported with Sole voting authority. No call or put options are reported in this table.
Material Changes and Comparisons
The filing text provided does not include data for the prior comparable period (e.g., December 31, 2025). Consequently, material changes in position size, value, or composition versus the prior quarter cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F is a regulatory disclosure of holdings and does not contain management commentary, financial guidance, or outlook for GSK Plc's core business operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the total aggregate value of GSK Plc's disclosed equity portfolio against the company's total assets to assess the significance of these investments.
- Compare these holdings with the previous quarter's 13F filing to identify new entries or exits in the biotech sector.
- Confirm whether these positions represent strategic partnerships or purely financial investments by cross-referencing with GSK's annual report (20-F).
- Note that the filing date (March 31, 2026) is in the future relative to current real-time; verify the actual filing date if this is a hypothetical or projected scenario.